Study aim: Comparing the effectiveness of the pharmaceutical combination of tamsulosin and ginseng with tamsulosin and licorice on clinical symptoms of patients with benign prostatic hyperplasia Design: A controlled clinical trial with parallel groups, without blinding, will be conducted in Phase 3 on 72 people. The rand function of Excel software will be used for randomization. Settings and conduct: This study will be conducted at Shahid Beheshti Hospital in Hamedan on patients with benign prostatic hyperplasia. In this study, patients will be randomly assigned to two treatment groups: ginseng capsules plus tamsulosin capsules and the second group will receive licorice tablets and tamsulosin. Both groups will be followed up for three months in terms of clinical symptoms. Participants/Inclusion and exclusion criteria: Participants will be patients with benign prostatic hyperplasia. Inclusion criteria for the study were age 50 to 70 years, IPSS equal to or greater than 8, PSA less than 4, residual urine volume less than 150 cc, and prostate volume greater than 30 cc. Exclusion criteria included history of treatment with anticholinergic drugs in the past month, history of prostate surgery, and recurrent or recurrent urinary tract infections. Intervention groups: Group 1: Ginseng capsules from Gol Daru Pharmaceutical Company (one every 12 hours) and Tamsulosin 0.4 mg capsules from Razak Pharmaceutical Company (one daily before bedtime) will be received. Group 2: Licorice tablets from Iran Daruk Pharmaceutical Company (one every 12 hours) and Tamsulosin 0.4 mg from Razak Pharmaceutical Company (one daily before bedtime). Main outcome variables: The main outcomes are urinary symptoms, sexual function, and medication side effects.